IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer

Genomic alterations (GA) in PIK3CA leads to the hyper-activation of the phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K) pathway in more than 20% of ovarian cancer (OC) patients. Therefore, PI3K therapies are under clinical evaluation for this subset of patients. Evidently, in clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Zorea, Jonatan, Prasad, Manu, Cohen, Limor, Li, Nan, Schefzik, Roman, Ghosh, Susmita, Rotblat, Barak, Brors, Benedikt, Elkabets, Moshe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148236/
https://www.ncbi.nlm.nih.gov/pubmed/30237504
http://dx.doi.org/10.1038/s41419-018-1025-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148236/
https://www.ncbi.nlm.nih.gov/pubmed/30237504
http://dx.doi.org/10.1038/s41419-018-1025-8

Ejemplares similares